postmenopausal

Estrone (Aquacrine) is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.

Elismetrep (MT-8554) is an orally available TRPM8 inhibitor with potential analgesic activity for the study of vasomotor symptoms in postmenopausal women.

WY-47766 (OST-766) is a small molecule proton pump inhibitor that can be used to study postmenopausal osteoporosis.

Diethylstilbestrol (DES) is used in the treatment of menopausal and postmenopausal disorders.

Raloxifene hydrochloride (LY156758 hydrochloride) is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Zoledronic Acid (ZOL 446) is a bisphosphonate. Zoledronic Acid (ZOL 446) is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronic Acid (ZOL 446) is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.

RU-16117, an 11 alpha-methoxy derivative of ethynyl estradiol, is an orally active weak estrogen that might be effective in treating estrogen deficiencies in postmenopausal women. This compound exhibits partial estrogen agonistic/antagonistic properties. RU-16117 can inhibit basal gonadotropin secretion and diminish the LH response to LHRH.

SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.

Raloxifene alkene (Compound 101) is a significant serum cholesterol-clearing agent. It exhibits notable antiproliferative activity against breast cancer cells. In an ovariectomized rat model, Raloxifene alkene effectively reduces serum cholesterol levels without significantly increasing uterine weight or the number of eosinophils in stromal cells. This compound is applicable for research into postmenopausal syndrome, particularly osteoporosis, estrogen-dependent breast cancer, and uterine cancer.

Bazedoxifene is a non-steroidal, orally active selective estrogen receptor modulator that exhibits activity against ERα and ERβ with IC50 values of 26 nM and 99 nM, respectively. Bazedoxifene also inhibits IL-6/GP130 protein interactions. Bazedoxifene is utilized in research on postmenopausal osteoporosis and pancreatic cancer, serving as a dual-purpose compound for hormonal and cytokine pathway investigations.

Strontium Malonate, a calcium-sensing receptor agonist, is used potentially for the treatment of postmenopausal osteoporosis.

17-Epiestriol is an endogenous metabolite of estrone formed via a 16α-hydroxy estrone intermediate followed by reduction of the C-17 ketone, and it binds estrogen receptor α and estrogen receptor β with relative binding affinities of 29 and 80 compared with 17β-estradiol, supporting its relevance in studies of estrogen signaling, metabolism, and receptor selectivity.

AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. AZD1981 has been used in trials studying the treatment and basic science of As

Bazedoxifene hydrochloride (TSE 424 hydrochloride) is an orally active, selective, and potent estrogen receptor modulator (SERM) that crosses the blood-brain barrier and is an inhibitor of IL-6/GP130 protein interactions with high affinity for ERα and ERβ. It has a high affinity for ERα and ERβ and can be used to study postmenopausal osteoporosis and vasodilator-related diseases.

Romosozumab (AMG-785) is a humanized monoclonal antibody that binds and inhibits sclerostin, increasing bone formation and decreasing bone resorption.Romosozumab is used in the study of postmenopausal osteoporosis.

Menotropin (Human Menopausal Gonadotropin) is a hormone discovered in the urine of postmenopausal women, possessing dual activity as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It promotes follicular growth and development, as well as the secretion of gonadal steroid hormones.

α-Cortolone, a metabolite of the glucocorticoid cortisol (hydrocortisone), is produced through the action of 20α-hydroxysteroid dehydrogenase (20α-HSD) via a tetrahydrocortisone (THE) intermediate. Studies indicate that urinary levels of α-cortolone are reduced in patients experiencing severe anorexia nervosa and postmenopausal women diagnosed with endometrial adenocarcinoma, in comparison to postmenopausal women without the condition.

GB-223 is a human monoclonal antibody (mAb) that targets TNFSF11/RANKL/CD254. It is applicable in the study of giant cell tumors of bone and postmenopausal osteoporosis.

1. Dalbergin (6-Hydroxy-7-Methoxy-4-Phenylcoumarin) exhibits similar bone conserving effect against bone-loss as estradiol treatment, it as a therapeutic candidate against postmenopausal osteoporosis. 2. Dalbergin prevents some effects of photoaging and maintain skin integrity by regulating the degradation of the extracellular matrix proteins.

Trilostane-D3 is a deuterium-substituted isotope-labeled compound of Trilostane (T1473), which is used primarily as a quantitative tracer. Trilostane is a competitive and specific inhibitor of 3-beta-hydroxysteroid dehydrogenase (3β-HSD), with the advantage of oral activity. Trilostane reduces the synthesis of steroid hormones by inhibiting the activity of 3β-HSD, and can be used in studies of Cushing's syndrome (hypercortisolism), Con's syndrome (hyperaldosteronism), and postmenopausal breast cancer.

Trans-Diethyl-1,1,1',1'-Stilbestrol-3,3',5,5'-D8 is a deuterated compound of Trans-Diethyl-Stilbestrol. Trans-Diethyl-Stilbestrol has a CAS number of 56-53-1. Diethylstilbestrol is used in the treatment of menopausal and postmenopausal disorders.

Estrone-D4 is a deuterated compound of Estrone. Estrone (T1009) has a CAS number of 53-16-7. Estrone (T1009) is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.

Estrone-D2 is a deuterated compound of Estrone. Estrone (T1009) has a CAS number of 53-16-7. Estrone (T1009) is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.

Diethylstilbestrol (Standard) is the standard substance of Diethylstilbestrol, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Diethylstilbestrol (DES) is used in the treatment of menopausal and postmenopausal disorders.